| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | METHOD FOR MODULATING THE EVOLUTION OF A POLYPEPTIDE ENCODED BY A NUCLEIC ACID SEQUENCE | EP05850658.5 | 2005-09-19 | EP1799823A2 | 2007-06-27 | MAZEL, Didier; CAMBRAY, Guillaume |
| A method for modulating the ability of a gene to mutate by analyzing codon usage within the gene and selecting a synonymous nucleotide sequence with a higher, lower or different capacity to mutate. The method permits widening and optimization of the evolutionary landscape of a protein. A computer-implemented method for analyzing and selecting nucleotide sequences with an altered ability to mutate. | ||||||
| 102 | METHOD FOR OBTAINING CELLS WITH NEW PROPERTIES | EP02767746.7 | 2002-07-08 | EP1404846A1 | 2004-04-07 | MUTZEL, Ruppert; MARLIERE, Philippe; MAZEL, Didier |
| The present invention relates to a method for generating a novel form of life comprising the steps consisting of: a) irreversible alteration of the genome of a microbial clone; b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate; c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a). | ||||||
| 103 | DESIGN OF MOLECULES | PCT/GB2010051940 | 2010-11-22 | WO2011061548A3 | 2011-08-11 | HOPKINS ANDREW LEE; BESNARD JEREMY |
| A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA 1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1-In) from the population (PG=0); and evaluating members (I1-In) of the initial population (Pparent) against at least one of the n achievement objectives (OA 1-x), where x is from 1 to n. | ||||||
| 104 | GENETIC SELECTION FOR PROTEIN FOLDING AND SOLUBILITY IN THE BACTERIAL PERIPLASM | PCT/US2008050991 | 2008-01-14 | WO2008089132A3 | 2008-11-13 | DELISA MATTHEW P; MANSELL THOMAS J; FISHER ADAM C |
| The present invention relates to the fields of microbiology, molecular biology and protein biochemistry. More particularly, it relates to compositions and methods for analyzing and altering (e.g., enhancing or inhibiting) protein folding and solubility (e.g., within periplasm). The present invention provides an engineered assay for protein folding and solubility in the E. coli periplasm based on co-translational translocation of a chimera comprising a protein of interest fused to TEM-I ß-lactamase that is targeted for export via the signal recognition particle (SRP)-dependent pathway. Using an array of native and heterologous proteins, it is demonstrated that periplasmic folding behavior of proteins is intimately coupled to in vivo ß-lactamase activity. As a result of this coupling, the reporter is useful for (1) facile discovery of extrinsic periplasmic factors that affect protein folding and solubility; and (2) genetic selection of solubility-enhanced proteins. | ||||||
| 105 | METHOD FOR OBTAINING CELLS WITH NEW PROPERTIES | PCT/IB0203398 | 2002-07-08 | WO03004656A8 | 2004-02-12 | MUTZEL RUPPERT; MARLIERE PHILIPPE; MAZEL DIDIER |
| The present invention relates to a method for generating a novel form of life comprising the steps consisting of: a) irreversible alteration of the genome of a microbial clone; b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate; c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a). | ||||||
| 106 | STRUCTURE-ACTIVITY RELATIONSHIPS | PCT/US2008001907 | 2008-02-12 | WO2009008908A3 | 2009-02-26 | MUNDORFF EMILY; DAVIS SIMON CHRISTOPHER; HUISMAN W GJALT; KREBBER ANKE; GRATE H JOHN |
| The present disclosure relates to compositions and methods for screening a plurality of polypeptide variants. | ||||||
| 107 | GENERATION OF LIBRARY OF SOLUBLE RANDOM POLYPEPTIDES LINKED TO mRNA | PCT/US2008053757 | 2008-02-12 | WO2008100961A3 | 2008-12-11 | WILLIAMS RICHARD B |
| Methods and compositions are provided for producing libraries of soluble random polypeptides. In the methods, the fraction of hydrophilic residues in the polypeptide is controlled so as to maintain the solubility of the polypeptide constructs. | ||||||
| 108 | EVOLVED ORTHOGONAL RIBOSOMES | PCT/GB2007004562 | 2007-11-28 | WO2008065398A3 | 2008-07-17 | CHIN JASON; WANG KAIHANG; NEUMANN HEINZ |
| There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules. | ||||||
| 109 | A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION | PCT/EP0104065 | 2001-04-04 | WO0175091A3 | 2002-04-18 | OHLIN MATS; SODERLIND ESKIL; CARLSSON ROLAND |
| The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the 'master framework'), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the 'original framework'), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same. | ||||||
| 110 | AUTONOMOUS IN VITRO EVOLUTION | PCT/US2009036065 | 2009-03-04 | WO2009111586A2 | 2009-09-11 | REIF JOHN H; SCHULTES ERIK A; LABEAN THOMAS H |
| Compositions and methods for the autonomous in vitro evolution of molecules having specific properties, employing one-pot continuous evolution are disclosed. | ||||||
| 111 | CELL SURFACE DISPLAY, SCREENING AND PRODUCTION OF PROTEINS OF INTEREST | PCT/US2008003978 | 2008-03-26 | WO2008118476A3 | 2008-11-13 | RAKESTRAW JAMES A; LIPOVSEK DASA |
| Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | ||||||
| 112 | METHOD FOR CARRYING OUT THE SELECTIVE EVOLUTION OF PROTEINS IN VITRO | PCT/EP2006007798 | 2006-08-07 | WO2007017229A3 | 2007-05-18 | LISS MICHAEL |
| The invention relates to the production of variants of a protein in an in vitro evolution method, comprising the steps: (A) preparing an in vitro expression system, comprising: (i) a nucleic acid sequence S, which codes for a protein Y to be varied; (ii) a target molecule X1 capable of binding to protein Y and/or at least one variant Y thereof; (iii) an RNA polymerase (Pol) capable of transcribing the nucleic acid sequence S; (iv) a reverse transcriptase (RT) capable of reverse transcribing transcripts of nucleic acid sequence S, the target molecule X being coupled to Pol and protein Y to RT, or target molecule X being coupled to RT and protein Y being coupled to Pol; (B) incubating the in vitro expression system from (A) under conditions that enable a transcription, a reverse transcription and a translation while forming variants Y' of protein Y and nucleic acid sequences S' coding therefor, and which promote the formation of variants Y' with improved binding properties for target molecule X; (C) isolating and optionally characterizing those variants Y' that have improved binding properties for binding to X and/or isolation nucleic acid sequence variants S' that code for Y'. | ||||||
| 113 | METHOD FOR MODULATING THE EVOLUTION OF A POLYPEPTIDE ENCODED BY A NUCLEIC ACID SEQUENCE | PCT/IB2005003317 | 2005-09-19 | WO2006046132A3 | 2006-08-17 | MAZEL DIDIER; CAMBRAY GUILLAUME |
| A method for modulating the ability of a gene to mutate by analyzing codon usage within the gene and selecting a synonymous nucleotide sequence with a higher, lower or different capacity to mutate. The method permits widening and optimization of the evolutionary landscape of a protein. A computer-implemented method for analyzing and selecting nucleotide sequences with an altered ability to mutate. | ||||||
| 114 | METHOD FOR OBTAINING CELLS WITH NEW PROPERTIES | PCT/IB0203398 | 2002-07-08 | WO03004656A9 | 2003-06-05 | MUTZEL RUPPERT; MARLIERE PHILIPPE; MAZEL DIDIER |
| The present invention relates to a method for generating a novel form of life comprising the steps consisting of: a) irreversible alteration of the genome of a microbial clone; b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate; c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a). | ||||||
QQ群二维码
意见反馈
意见反馈